Results Snapshot
Figures in Cr
Standalone Annual Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Annual Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2026 is 2.66% vs 5.57% in Mar 2025
Standalone Net Profit
YoY Growth in year ended Mar 2026 is -1.87% vs -7.86% in Mar 2025
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2026 is -12.15% vs -14.55% in Mar 2025
Interest
YoY Growth in year ended Mar 2026 is 62.50% vs -27.27% in Mar 2025
Operating Profit Margin (Excl OI)
YoY Growth in year ended Mar 2026 has fallen from Mar 2025
Compare Annual Results Of Par Drugs & Che. With
Figures in Cr
Standalone Annual Results
Change(INR)
Change(%)
Net Sales
103.66
1,043.71
-940.05
-90.07%
Other Operating Income
0.00
0.00
0.00
Total Operating income
103.66
1,043.71
-940.05
-90.07%
Raw Material Cost
42.67
854.89
-812.22
-95.01%
Purchase of Finished goods
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.69
11.32
-10.63
-93.90%
Employee Cost
6.12
38.76
-32.64
-84.21%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
37.05
123.28
-86.23
-69.95%
Total Expenditure (Excl Depreciation)
86.53
1,028.25
-941.72
-91.58%
Operating Profit (PBDIT) excl Other Income
17.13
15.46
1.67
10.80%
Other Income
4.00
1.62
2.38
146.91%
Operating Profit (PBDIT)
21.13
17.08
4.05
23.71%
Interest
0.13
0.36
-0.23
-63.89%
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
21.00
16.72
4.28
25.60%
Depreciation
3.70
5.30
-1.60
-30.19%
Profit Before Tax
17.30
11.42
5.88
51.49%
Tax
4.19
3.12
1.07
34.29%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
13.11
8.30
4.81
57.95%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
13.11
8.30
4.81
57.95%
Equity Capital
12.30
8.88
3.42
38.51%
Face Value
10.00
10.00
0.00
Reserves
99.68
204.51
-104.83
-51.26%
Earnings per share (EPS)
10.66
9.35
1.31
14.01%
Diluted Earnings per share
10.65
9.35
1.30
13.90%
Operating Profit Margin (Excl OI)
16.53%
1.48%
0.00
15.05%
Gross Profit Margin
20.26%
1.60%
0.00
18.66%
PAT Margin
12.65%
0.80%
0.00
11.85%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Annual - Net Sales
Net Sales 103.66 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 2.66% vs 5.57% in Mar 2025
Annual - Standalone Net Profit
Standalone Net Profit 13.11 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is -1.87% vs -7.86% in Mar 2025
Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 17.13 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is -12.15% vs -14.55% in Mar 2025
Annual - Interest
Interest 0.13 Cr
in Mar 2026Figures in Cr
YoY Growth in year ended Mar 2026 is 62.50% vs -27.27% in Mar 2025
Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 16.53%
in Mar 2026Figures in %
YoY Growth in year ended Mar 2026 has fallen from Mar 2025






